Previous 10 | Next 10 |
Conference call begins at 4:30 p.m. Eastern time today NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, reports financial results for the three and nine months ended...
Prescription-strength CelleRx to gently clean skin and ease post-procedure discomfort is now available without a prescription at www.CelleRx.com NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces the availability of full-strength CelleRx for consumer purchase with...
NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces that it will report third quarter 2019 financial results after market close on Thursday, November 7, 2019 and will ...
Once-daily system complements Avenova and leverages salesforce calls on eyecare specialists NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces an exclusive 90-...
NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces that it has received approval for the distribution of Avenova from the Australian Government Department of Health a...
Axsome Therapeutics (NASDAQ: AXSM ) initiated with Outperform rating at William Blair. Shares up 1% premarket. More news on: Axsome Therapeutics, Inc., Canopy Growth Corporation, Minerva Neurosciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces that Yenyou (Jeff) Zheng, Ph.D. has joined the Company’s board as an independent director. Dr. Zheng will ch...
NovaBay ® Pharmaceuticals, Inc . (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces that management will present at two upcoming investment conferences: RHK Capital 4 th Annual Disruptive Growth C...
NovaBay Pharmaceuticals ( NBY -14.8% ) is down on below-average volume on the heels of its agreement to sell ~4.2M common shares and accompanying unregistered five-year warrants to purchase up to the same number of shares at $1.15 to institutional investors at $1 per share and warrant. C...
EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with...
News, Short Squeeze, Breakout and More Instantly...
NovaBay Pharmaceuticals Inc. Company Name:
NBY Stock Symbol:
NYSE Market:
NovaBay Pharmaceuticals Inc. Website:
NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Ea...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reports record sales of Avenova ® -branded eyecare products during the Amazon Prime Day event, which was held July 16-17, 2024. Over the two-day period, Avenova sales were 17% higher compared with Prime Day 2023 and were up 40% over ...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants, Series F-1 warrants, Series F-2 warrants and Series F-3 warrants f...